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DCames H. F. Rudd, Jagat Narula, H. William Strauss, Renu Virmani, Josef Machac, Mike Klimas,
obuhiro Tahara, Valentin Fuster, Elizabeth A. Warburton, Zahi A. Fayad, Ahmed A. Tawakol
nflammation is a determinant of atherosclerotic plaque rupture, the event leading to
ost myocardial infarctions and strokes. Conventional imaging techniques only
dentify the site and severity of luminal stenosis. Positron emission tomographic
PET) imaging of atherosclerosis using the metabolic marker fluorodeoxyglucose
FDG) allows quantification of arterial inflammation. This review by Rudd and
olleagues sets out the background and current and potential future applications of this
merging biomarker of cardiovascular risk, along with its limitations, particularly imaging
he coronary arteries.CLINICAL RESEARCH NTERVENTIONAL CARDIOLOGY2536Long-Term Safety and Efficacy of a Dual-DES19.3
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6-8 m    2 yrs 6-8 m    2 yrsobert A. Byrne, Adnan Kastrati, Klaus Tiroch, Stefanie Schulz, Jürgen Pache, Susanne Pinieck,
teffen Massberg, Melchior Seyfarth, Karl-Ludwig Laugwitz, Katrin A. Birkmeier, Albert Schömig,
ulinda Mehilli, for the ISAR-TEST-2 Investigators
n the ISAR-TEST-2 (Intracoronary Stenting and Angiographic Results: Test Efficacy of
hree Limus-Eluting Stents) trial, subjects were randomized to sirolimus-eluting stents
SES), zotarolimus-eluting stents (ZES), or a novel dual drug-eluting stent (Dual-DES),
hich elutes both sirolimus and probucol using a polymer-free drug release system. There
ere no significant differences between the groups for death/myocardial infarction or definite
tent thrombosis. The 2-year target lesion revascularization (TLR) was lowest with Dual-
ES. Incident TLR between 1 and 2 years was lower in the Dual-DES group than with
ES, but comparable with ZES. At 2 years there was no signal of a differential safety profile
etween the 3 stent platforms, but Dual-DES reduced the incidence of TLR.(continued on page A-22)
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ENTERVENTIONAL CARDIOLOGY
2544resence of Multivessel Disease Does Not Alter Relative Efficacy
of CABG Compared With PCI for Left Main Lesionsoung-Hak Kim, Duk-Woo Park, Won-Jang Kim, Jong-Young Lee, Sung-Cheol Yun, Soo-Jin Kang,
eung-Whan Lee, Cheol Whan Lee, Myeong-Ki Hong, Seong-Wook Park, Seung-Jung Park
im and colleagues used a nationwide registry to determine if the extent of coronary disease
ffected long-term outcomes after coronary stenting or coronary artery bypass graft (CABG)
urgery for unprotected left main coronary artery (ULMCA) stenosis. More than 2,000
atients with ULMCA stenosis who underwent either stenting or CABG were stratified by
he number of diseased vessels. After adjustment for EuroSCORE (European System for
ardiac Operative Risk Evaluation), diabetes, and bifurcation stenosis, stents and CABG had
imilar risks of death and major adverse cardiac events excluding target vessel revascularization
TVR) over 4 years, regardless of the number of diseased vessels. In patients with 2- or 3-
essel disease, however, stenting was associated with a higher risk of TVR. These results
uggest that stenting may be a safe alternative to CABG in patients with ULMCA stenosis
ombined with additional coronary lesions.ditorial Comment: Barry F. Uretsky, p. 2553CUTE CORONARY SYNDROMES2556Practical Risk Score Predicts Risk of Bleeding for ACS Patientsoxana Mehran, Stuart J. Pocock, Eugenia Nikolsky, Tim Clayton, George D. Dangas, Ajay J. Kirtane,
elen Parise, Martin Fahy, Steven V. Manoukian, Frederick Feit, Magnus E. Ohman,
ernard Witzenbichler, Giulio Guagliumi, Alexandra J. Lansky, Gregg W. Stone
ehran and colleagues used data from over 17,000 subjects enrolled in the ACUITY
Acute Catheterization and Urgent Intervention Triage strategY) and HORIZONS-AMI
Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial
nfarction) trials to develop a simple formula to predict the risk of bleeding. Seven percent of
ubjects had non-coronary artery bypass graft surgery (CABG)-related major bleeding within
0 days. This risk was predicted by 6 independent baseline variables (female sex, advanced
ge, elevated serum creatinine and white blood cell count, anemia, non–ST-segment elevation
yocardial infarction [STEMI] with raised biomarkers, or STEMI). The risk was also higher
ith the use of heparin  a glycoprotein IIb/IIIa inhibitor rather than bivalirudin alone. The
isk score differentiated patients with a 30-day rate of non–CABG-related major bleeding
anging from 1% to over 40%. The risk of major bleeding in ACS patients can be estimated
rom 6 factors; this knowledge may be useful for both stratification and determining the
ptimal anticoagulation regimen.
ditorial Comment: Jeffrey Brinker, p. 2567(continued on page A-23)
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hEART RHYTHM DISORDERS2570Effects of Screening Family Members for an Inherited Arrhythmiaynke Hofman, Hanno L. Tan, Marielle Alders, Irene M. van Langen, Arthur A. M. Wilde
hile genetic screening can now be performed for the 3 primary inherited arrhythmias
congenital long QT syndrome [LQTS], catecholaminergic polymorphic ventricular
achycardia [CPVT], and Brugada syndrome [BrS]), it is not known how this affects the
reatment of family members carrying the mutation. After establishing the disease-causing
eoxyribonucleic acid mutation in probands, Hofman and colleagues actively conducted
ascade screening to identify relatives who carry the mutation. A total of 130 probands with
disease-causing mutation were identified, and 509 relatives tested positive for the disease-
ausing familial mutation. During follow-up, treatment was initiated and ongoing in 65%,
1%, and 6% of the affected relatives in the LQTS, CPVT, and BrS families, respectively.
reatment included medical therapy, primarily beta-blockers, or implantation of a pacemaker
r implantable cardioverter-defibrillator.ditorial Comment: Peter J. Schwartz, p. 2577IPID THERAPY2580RVX-208: A Small Molecule That Increases ApoA-I and HDLana Bailey, Ravi Jahagirdar, Allan Gordon, Anouar Hafiane, Steven Campbell, Safia Chatur,
regory S. Wagner, Henrik C. Hansen, Fabrizio S. Chiacchia, Jan Johansson, Larbi Krimbou,
orman C. W. Wong, Jacques Genest
ailey and colleagues describe their initial studies with a novel small molecule, RVX-208, and
ts effects on apolipoprotein (apo)A-I and high-density lipoprotein (HDL) cholesterol levels
n vitro and in vivo. RVX-208 induced apoA-I messenger ribonucleic acid and protein
ynthesis in HepG2 cells leading to increased levels of pre--migrating and -lipoprotein
articles containing apoA-I. In African green monkeys, RVX-208 treatment for 63 days
ncreased serum apoA-I and HDL cholesterol levels (60% and 97%, respectively). Treatment
f humans for 1 week increased apoA-I, pre--HDL, and HDL functionality. These data
uggest that RVX-208 should be further studied to determine its safety and efficacy in
umans as a treatment for atherosclerosis.(continued on page A-24)
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cIOMARKERS2590H-FABP Predicts Outcomes in Troponin-Negative Patients With Suspected ACSarthik Viswanathan, Niamh Kilcullen, Christine Morrell, Sue J. Thistlethwaite, Mohan U. Sivananthan,
ajek B. Hassan, Julian H. Barth, Alistair S. Hall
eart-type fatty acid binding protein (H-FABP) is a low-molecular-weight cytoplasmic
rotein; animal studies suggest that it is released into the bloodstream with as little as 15 min
f ischemia. Viswanathan and colleagues enrolled almost 1,000 subjects with suspected acute
oronary syndrome (ACS) and measured H-FABP and troponin on samples collected 12 to
4 h from symptom onset. After multivariate adjustment, patients with H-FABP concentrations
6.48 g/l had significantly increased risk of adverse events, even when troponin levels
ere negative. These results suggest that the prognostic value of H-FABP is additive to
roponin in patients with suspected ACS.NDOTHELIAL FUNCTION2599Stress of Caring for Someone With Dementia May Impair Endothelial Functionrent T. Mausbach, Susan K. Roepke, Michael G. Ziegler, Milos Milic, Roland von Känel, Joel E. Dimsdale,
aul J. Mills, Thomas L. Patterson, Matthew A. Allison, Sonia Ancoli-Israel, Igor Grant
ausbach and colleagues investigated the relationship between chronic caregiver stress and
ndothelial dysfunction assessed by reactive hyperemia-induced flow-mediated dilation
FMD). Seventy-eight elderly individuals participated in the study, approximately two-thirds
f whom were providing in-home care to a spouse with Alzheimer’s disease (AD). Clinical
ementia Rating scores for the spouse were significantly related to FMD in the participants.
oth the severity of dementia and the number of years of caregiving were significantly related
o FMD. These results suggest that the chronic stress of caring for someone with AD
mpairs endothelial function and may be the mechanistic link explaining the increased risk for
ardiovascular disease in elderly caregivers.
